ProMIS Neurosciences Inc. (PMN)
Last updated: 2026-10-21 08:05:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
ProMIS Neurosciences Inc. (PMN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.09, with a market capitalization of $73.80M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.27 to $27.40. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$73.80M | |
$7.85 | |
$350.00 | |
$6.27 | |
$8.09 | |
-- | |
68.56K | |
-- | |
$27.40 | |
$6.27 | |
-- | |
-- |
ProMIS Neurosciences Inc. (PMN) Pre-Market Stock Price
ProMIS Neurosciences Inc. (PMN) is trading at $8.09 in pre-market trading as of 2026-10-21 08:02:00, down 0.01% ($0.00) from the previous close of $8.09
Pre-market trading shows how investors are pricing PMN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
ProMIS Neurosciences Inc. (PMN) 7-Day Stock Price Change
Over the past seven days, ProMIS Neurosciences Inc. (PMN) moved from $9.45 to $8.09, representing a decline of 14.40% ($1.36).
The stock traded between $7.85 and $9.78 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 24.26 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
PMN 52-Week Price Position
Position in Range: 8.6%
PMN is currently trading at $8.09, placing it 8.6% of the way from its 52-week low of $6.27 to its 52-week high of $27.40. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is ProMIS Neurosciences Inc. (PMN)?
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
ProMIS Neurosciences Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 11 |
| Exchange | NASDAQ |
| Company Website |
How to Buy ProMIS Neurosciences Inc. (PMN) Stock on MEXC
Eligible investors can buy real shares of ProMIS Neurosciences Inc. (PMN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is ProMIS Neurosciences Inc. (PMN) stock price today?
2.Is PMN stock going up or down today?
3.What is PMN pre-market price?
4.What is PMN after-hours price?
5.Is PMN stock trading now?
6.Where does PMN sit relative to its 52-week high and low?
7.What sector is ProMIS Neurosciences Inc. in?
8.What is ProMIS Neurosciences Inc.'s market capitalization and where is it listed?
9.How is PMN valued in terms of P/E ratio and EPS?
10.Does ProMIS Neurosciences Inc. pay a dividend?
Explore More US Stocks
Search Stocks
PMN Stock Calculator
Estimate the value between PMN shares and USD.
PMN Shares to USD
1.00 PMN shares = 8.089 USD
Calculations are estimates based on the latest available price and are for reference only.


